All News

Middle-aged and older men undergoing testosterone replacement therapy aren’t at increased risk of venous thromboembolism (VTE), the results of a large comparative case-control analysis published online in Mayo Clinic Proceedings (July 15, 2015) suggest.

A new study reports no statistically significant increase in the risk of bladder cancer among patients treated with the diabetes drug pioglitazone (Actos), despite previous studies suggesting an association.

The three most commonly performed sling procedures exhibit long-term success, according to a recent observational study presented at the AUA annual meeting in New Orleans.

With conflicting data, should docetaxel be used up front in newly diagnosed metastatic disease?

Treatment with metformin plus a statin appears to pay huge dividends in high-risk prostate cancer patients, data from a large study show.

Docetaxel (Taxotere) added to standard hormone therapy extended mean survival by about 10 months, according to a recent large-scale study.

In nearly every survey of physician sentiment, doctors cite administrative burdens associated with payer relations as distracting from patient care and the performance of their chosen profession.

“It is a positive thing, because the technology we’re using now is not really very accurate," one urologist told Urology Times.

“It is a positive thing, because the technology we’re using now is not really very accurate," one urologist told Urology Times.

In this interview, Inderbir S. Gill, MD, MCh, discusses what he calls the three most significant advances in minimally invasive oncologic surgery, how the current model for education can be improved, and the next frontier in minimally invasive surgery.

Raoul S. Concepcion, MD, uses his group's experience to illustrate how other urology groups can successfully incorporate APPs into their practice model and provide state-of-the-art care.

In this round-up of new urology products and services, learn about an app that helps moviegoers with OAB, a new mesh for sacrocolpopexy, and device/smartphone app that help women with pelvic floor exercises.

According to a population-based assessment of the risk factors for bladder slings used to treat stress urinary incontinence in women, provider volume impacts the incidence of mesh removal or revision.

Innovation has been the underpinning of American medicine for decades. However, as we move deeper into the 21st century, it is important to assess whether we are providing an environment where a culture of innovation can thrive.

Unfortunately, there is no “one-size-fits-all” answer to when you should start receiving Social Security benefits.

The AUA Coding and Reimbursement Committee, American Academy of Pediatric Urology, urology fellows of the American Academy of Pediatrics, and members of the Pediatric Urology Coordinating Council of the Society of Pediatric Urology recently published a consensus document on suggested coding guidance for pediatric hypospadias repair.

For the practicing physician, MACRA introduces a new fork in the road and a freeway to the future.

The reality of ICD-10 and what it means to physicians’ practices will come into focus beginning Oct. 1. But there are things that specifically urologists should know in the days, weeks, and dwindling months before adopting the code set becomes the new normal.

In most states, the standard for obtaining consent includes discussion of risks versus benefits, some known complications, and any alternative treatment options.

Congress doesn’t appear to like very much President Obama’s FY 2016 budget proposal to eliminate funding for Centers for Disease Control and Prevention activities that are focused on education about prostate cancer screening and treatment, as well as tracking disease incidence and mortality data.

This article focuses on the the Centers for Medicare & Medicaid Services' recently released 2013 utilization and payment data and what they tell us about the business of urology.

A novel investigational oral testosterone replacement therapy restored and maintained testosterone levels to a eugonadal range in 88% of hypogondal men treated with the agent in a randomized clinical trial.

ARN-509, a novel oral antiandrogen, was safe, well tolerated, and showed promising efficacy in men with high-risk, non-metastatic castration-resistant prostate cancer (CRPC) in a phase II study, reported Neal D. Shore, MD.

Use of testosterone replacement therapy more than tripled between 2003 and 2012 in a population of reproductive-age men, according to a study presented at the AUA annual meeting in New Orleans.

Higher radiation doses don’t confer a survival benefit in men with low-risk prostate cancer, although they do increase survival rates for men with medium- and high-risk cancers, the authors of a new study report.

Mini-laparoscopic surgery has evolved since its initial introduction, but its benefits are still the subject of debate.

While there is no benefit from using tamsulosin (Flomax) versus placebo for the treatment of small ureteral stones, there is a potential upside of increased passage from using the drug to treat 5- to 10-mm stones, according to a study from Australia published online in the Annals of Emergency Medicine (July 13, 2015).

A recently published review expands understanding of the effectiveness and side effects of mid-urethral sling procedures for stress urinary incontinence, providing more information for women considering minimally invasive surgical treatment.